Skip to main content

Advertisement

SpringerLink
Log in

The role of biomarkers in the management of patients with rheumatoid arthritis

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

In recent years, patient outcomes have improved dramatically with the availability of effective treatments for the management of rheumatoid arthritis (RA). RA, however, is a heterogeneous disease with variable disease progression and treatment response. Whereas some patients respond to a single disease-modifying antirheumatic drug, others require more intensive treatment strategies. Assessing disease severity at diagnosis and monitoring disease activity on an individual level would be a more accurate way of tailoring therapy, ensuring optimal treatment for those at greatest risk of disease progression, long-term disability, and joint damage without unnecessary overtreatment. Assessment of disease activity and severity is currently based on a combination of clinical and laboratory parameters that aid treatment decisions. Use of biomarkers may provide a more accurate means of objectively assessing the disease. This article reviews the role of biomarkers in the management of RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Maini R, St Clair EW, Breedveld F, et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932–1939.

    Article  PubMed  CAS  Google Scholar 

  2. Klareskog L, van der Heijde D, de Jager JP, et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675–681.

    Article  PubMed  CAS  Google Scholar 

  3. Brown AK, Conaghan PG, Karim Z, et al.: An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008, 58:2958–2967.

    Article  PubMed  CAS  Google Scholar 

  4. Smolen JS, Aletaha D, Grisar J, et al.: The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthritis Res Ther 2008, 10:208.

    Article  PubMed  Google Scholar 

  5. Emery P, McInnes IB, van Vollenhoven R, Kraan MC: Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:392–398.

    Article  CAS  Google Scholar 

  6. Marotte H, Pallot-Prades B, Grange L, et al.: The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006, 65:342–347.

    Article  PubMed  CAS  Google Scholar 

  7. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al.: Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008, 58:1293–1298.

    Article  PubMed  Google Scholar 

  8. Criswell LA, Lum RF, Turner KN, et al.: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004, 50:2750–2756.

    Article  PubMed  CAS  Google Scholar 

  9. Potter C, Hyrich KL, Tracey A, et al.: Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:69–74.

    Article  PubMed  CAS  Google Scholar 

  10. Padyukov L, Lampa J, Heimburger M, et al.: Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003, 62:526–529.

    Article  PubMed  CAS  Google Scholar 

  11. Pinto JA, Rego I, Rodriguez-Gomez M, et al.: Polymorphisms in genes encoding tumor necrosis factor-alpha and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis. J Rheumatol 2008, 35:177–178.

    PubMed  Google Scholar 

  12. Szodoray P, Szabo Z, Kapitany A, et al.: Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev 2009 May 7 (Epub ahead of print).

  13. Hughes LB, Danila MI, Bridges SL: Recent advances in personalizing rheumatoid arthritis therapy and management. Personalized Medicine 2009, 6:159–170.

    Article  CAS  Google Scholar 

  14. Plenge RM, Criswell LA: Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008, 20:145–152.

    Article  PubMed  CAS  Google Scholar 

  15. Bukhari M, Lunt M, Harrison BJ, et al.: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002, 46:906–912.

    Article  PubMed  CAS  Google Scholar 

  16. Meyer O, Labarre C, Dougados M, et al.: Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003, 62:120–126.

    Article  PubMed  CAS  Google Scholar 

  17. Berglin E, Johansson T, Sundin U, et al.: Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006, 65:453–458.

    Article  PubMed  CAS  Google Scholar 

  18. Bos WH, Bartelds GM, Wolbink GJ, et al.: Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008, 35:1972–1977.

    PubMed  CAS  Google Scholar 

  19. Bruns A, Nicaise-Roland P, Hayem G, et al.: Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Joint Bone Spine 2009, 76:248–253.

    Article  PubMed  Google Scholar 

  20. Cuchacovich M, Catalan D, Wainstein E, et al.: Basal anticyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. Clin Exp Rheumatol 2008, 26:1067–1073.

    PubMed  CAS  Google Scholar 

  21. Visser K, Verpoort KN, van Dongen H, et al.: Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recentonset arthritis. Ann Rheum Dis 2008, 67:1194–1195.

    Article  PubMed  CAS  Google Scholar 

  22. Nakamura RM: Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis. J Clin Lab Anal 2000, 14:305–313.

    Article  PubMed  CAS  Google Scholar 

  23. Smolen JS, Van Der Heijde DM, St Clair EW, et al.: Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006, 54:702–710.

    Article  PubMed  CAS  Google Scholar 

  24. Buch MH, Seto Y, Bingham SJ, et al.: C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. Arthritis Rheum 2005, 52:42–48.

    Article  PubMed  CAS  Google Scholar 

  25. Emery P, Gabay C, Kraan M, Gomez-Reino J: Evidencebased review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int 2007, 27:793–806.

    Article  PubMed  CAS  Google Scholar 

  26. Buch MH, Reece RJ, Quinn MA, et al.: The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). Rheumatology (Oxford) 2008, 47:1469–1475.

    Article  CAS  Google Scholar 

  27. Fabre S, Dupuy AM, Dossat N, et al.: Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. Clin Exp Immunol 2008, 153:188–195.

    Article  PubMed  CAS  Google Scholar 

  28. Gerlag DM, Tak PP: Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract Res Clin Rheumatol 2008, 22:311–323.

    Article  PubMed  CAS  Google Scholar 

  29. Kraan MC, Haringman JJ, Weedon H, et al.: T cells, fibroblast-like synoviocytes, and granzyme B+ cytotoxic cells are associated with joint damage in patients with recent onset rheumatoid arthritis. Ann Rheum Dis 2004, 63:483–488.

    Article  PubMed  CAS  Google Scholar 

  30. Bresnihan B, Gerlag DM, Rooney T, et al.: Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol 2007 34:620–622.

    PubMed  Google Scholar 

  31. Kavanaugh A, Rosengren S, Lee SJ, et al.: Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008, 67:402–408.

    Article  PubMed  CAS  Google Scholar 

  32. Vos K, Thurlings RM, Wijbrandts CA, et al.: Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007, 56:772–778.

    Article  PubMed  CAS  Google Scholar 

  33. Humby F, Manzo A, Kirkham B, Pitzalis C: The synovial membrane as a prognostic tool in rheumatoid arthritis. Autoimmun Rev 2007, 6:248–252.

    Article  PubMed  Google Scholar 

  34. Dass S, Rawstron AC, Vital EM, et al.: Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993–2999.

    Article  PubMed  CAS  Google Scholar 

  35. Burgoyne CH, Field SL, Brown AK, et al.: Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Ann Rheum Dis 2008, 67:750–757.

    Article  PubMed  CAS  Google Scholar 

  36. Young-Min S, Cawston T, Marshall N, et al.: Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007, 56:3236–3247.

    Article  PubMed  CAS  Google Scholar 

  37. Visvanathan S, Marini JC, Smolen JS, et al.: Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. J Rheumatol 2007, 34:1465–1474.

    PubMed  CAS  Google Scholar 

  38. Green MJ, Gough AK, Devlin J, et al.: Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003, 42:83–88.

    Article  CAS  Google Scholar 

  39. Tchetverikov I, Lard LR, DeGroot J, et al.: Matrix metal-loproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:1094–1099.

    Article  PubMed  CAS  Google Scholar 

  40. Garnero P, Gineyts E, Christgau S, et al.: Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:21–30.

    Article  PubMed  CAS  Google Scholar 

  41. Verstappen SM, Poole AR, Ionescu M, et al.: Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Res Ther 2006, 8:R31.

    Article  PubMed  CAS  Google Scholar 

  42. Landewe R, Geusens P, Boers M, et al.: Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004, 50:1390–1399.

    Article  PubMed  CAS  Google Scholar 

  43. Mullan RH, Matthews C, Bresnihan B, et al.: Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum 2007, 56:2919–2928.

    Article  PubMed  CAS  Google Scholar 

  44. Crnkic M, Mansson B, Larsson L, et al.: Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003, 5:R181–R185.

    Article  PubMed  CAS  Google Scholar 

  45. Morozzi G, Fabbroni M, Bellisai F, et al.: Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007, 26:1335–1338.

    Article  PubMed  CAS  Google Scholar 

  46. Marotte H, Gineyts E, Miossec P, Delmas PD: Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. Ann Rheum Dis 2009, 68:1197–1200.

    Article  PubMed  CAS  Google Scholar 

  47. Geusens PP, Landewe RB, Garnero P, et al.: The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 2006, 54:1772–1777.

    Article  PubMed  CAS  Google Scholar 

  48. Hakala M, Risteli J, Aman S, et al.: Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. Scand J Rheumatol 2008, 37:90–93.

    Article  PubMed  CAS  Google Scholar 

  49. Syversen SW, Goll GL, van der Heijde D, et al.: Cartilage and bone biomarkers in rheumatoid arthritis: prediction of 10-year radiographic progression. J Rheumatol 2009, 36:266–272.

    Article  PubMed  CAS  Google Scholar 

  50. Keeling SO, Landewe R, van der Heijde D, et al.: Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol 2007, 34:623–633.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Unit of Musculoskeletal Diseases, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK

    Paul Emery

Authors
  1. Jackie Nam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edith Villeneuve
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Emery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Emery.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nam, J., Villeneuve, E. & Emery, P. The role of biomarkers in the management of patients with rheumatoid arthritis. Curr Rheumatol Rep 11, 371–377 (2009). https://doi.org/10.1007/s11926-009-0053-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0053-x

Keywords

Search

Navigation